vimarsana.com
  1. Home
  2. Live Updates
  3. Fixed Dose Combination Tablet Formula - Breaking News

Fixed Dose Combination Tablet Formula News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NewAmsterdam Pharma Company B V : NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023

- Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p - 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of - New Data Demonstrate

United statesNoord hollandHannah deresiewiczChristiem ballantyneMatthew philippeCompany phaseExchange commissionCompany contactCardiovascular researchFrazier lifesciences acquisition corporationNational lipid associationNeither the companyNewamsterdam pharma companynv nasdaqBaylor college of medicineMenarini groupPrimary endpoint

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.